Sage advice: psychiatric drug development is tough
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Biogen teases with lupus ahead of aducanumab's big Alzheimer’s reveal
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
Puretech’s cautionary tale about pivotal study read-across
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Supernus’s latest failure leaves its future looking dim
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
Shock revelation sees Biogen erase its aducanumab losses
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Upcoming events – Sage targets depression and Biogen aims for lupus
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.